Related Experiment Videos
Retinoblastoma recurrence after iodine 125 plaque application
C W Spraul1, J I Lim, S R Lambert
1Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA.
Retina (Philadelphia, Pa.)
|January 1, 1996
Summary
Recurrent retinoblastoma after iodine 125 plaque therapy may arise from radioresistant, well-differentiated cells. This case highlights potential treatment challenges in pediatric eye cancer.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Radiation Oncology
Background:
- Retinoblastoma is the most common primary intraocular malignancy in children.
- Radioactive iodine 125 (125I) plaque therapy is a common treatment for retinoblastoma.
- Recurrence after treatment necessitates further investigation and management strategies.
Observation:
- A case of recurrent retinoblastoma in a 1-year-old boy following 125I plaque therapy is presented.
- Histopathologic examination of the enucleated eye revealed a bimodal tumor cell population.
- Immunohistochemical analysis showed positivity for glial fibrillary acid protein and S-100 protein in well-differentiated tumor cells.
Findings:
- The recurrent tumor exhibited both poorly differentiated and well-differentiated cell populations.
- The well-differentiated component, characterized by fleurettes, stained positive for glial fibrillary acid protein and S-100 protein.
- These findings suggest that radioresistant, well-differentiated cells may contribute to treatment failure.
Implications:
- This case underscores the potential for radioresistance in specific retinoblastoma cell types.
- Understanding the behavior of differentiated cells is crucial for optimizing retinoblastoma treatment.
- Further research into radioresistant mechanisms in retinoblastoma is warranted.